No CrossRef data available.
Article contents
Endocrine disorders
Published online by Cambridge University Press: 17 November 2008
Abstract
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Clinical geriatrics
- Information
- Copyright
- Copyright © Cambridge University Press 1993
References
2Belchetz, PE.Gonadotrophin regulation and clinical applications of GnRH. Clin Endocrinol Metab 1983; 12: 619–40.CrossRefGoogle ScholarPubMed
3Belchetz, PE, Plant, TM, Nakai, Y et al. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science 1978; 202: 631–33.CrossRefGoogle Scholar
4Casper, RF, Yen, SSC, Wilkes, MM.Menopausal flushes: a neuroendocrine link with pulsatile luteinizing hormone secretion. Science 1979; 205: 823–25.CrossRefGoogle Scholar
5Mulley, G, Mitchell, JRA, Tattersall, RB.Hot flushes after hypophysectomy. Br Med J 1977; 2: 1062.CrossRefGoogle ScholarPubMed
6Coope, JM, Thompson, JM, Poller, L.Effects of ‘natural oestrogen’ replacement therapy on menopausal symptoms and blood clotting. Br Med J 1975; 4: 139–43.CrossRefGoogle ScholarPubMed
7Draper, J, Roland, M.Perimenopausal women's views on taking hormone replacement therapy to prevent osteoporosis. Br Med J 1990; 300: 786–88.CrossRefGoogle ScholarPubMed
8Wallace, WA, Price, VH, Elliot, CA et al. Hormone replacement therapy acceptability to Nottingham post-menopausal women with a risk-factor for osteoporosis. J R Soc Med 1990; 83: 699–701.CrossRefGoogle ScholarPubMed
9Belchetz, PE.Hormone replacement treatment. Deserves wider use. Br Med J 1989; 298: 1467–68.CrossRefGoogle Scholar
10Hillner, BE, Hollenberg, JP, Pauker, SG.Postmenopausal estrogens in prevention of osteoporosis. Benefit virtually without risk if cardiovascular effects are considered. Am J Med 1986; 80: 1115–27.CrossRefGoogle ScholarPubMed
11Stampfer, MJ, Colditz, GA.Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47–63.CrossRefGoogle ScholarPubMed
12Barrett-Connor, E.Postmenopausal estrogen and prevention bias. Ann Intern Med 1991; 115: 455–56.CrossRefGoogle ScholarPubMed
13Smith, DC, Prentice, R.Thompson, DJ, Herrmann, WL.Association of exogenous estrogens and endometrial carcinoma. N Engl J Med 1975; 293: 1164–67.CrossRefGoogle ScholarPubMed
14Robboy, SJ, Bradley, R.Changing trends and prognostic features in endometrial cancer associated with exogenous estrogen therapy. Obstet Gynecol 1979; 54: 269–77.Google ScholarPubMed
15Voigt, L, Weiss, NS, Chu, J et al. Progestogen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338: 274–77.CrossRefGoogle ScholarPubMed
16Rijpkema, AHM, van der Sanden, AA, Ruijs, AHC.Effects of post-menopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review. Maturitas 1990; 12: 259–85.CrossRefGoogle ScholarPubMed
17Lobo, RA, Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 1991; 73: 925–30.CrossRefGoogle ScholarPubMed
18Mann, RD ed. Hormone replacement therapy and breast cancer risk. Camforth: Parthenon, 1992.Google ScholarPubMed
20Carlson, HE. Gynecomastia In: Morley, JE, Korenman, SG eds. Endocrinology and metabolism in the elderly. Boston: Blackwell, 1992; 293–306.Google Scholar
21Belchetz, P. Male hypogonadism. In: Grossman, A ed. Clinical endocrinology. Oxford: Blackwell, 1992: 632–53.Google Scholar
22Anderson, DC.Sex hormone-binding globulin. Clin Endocrinol (Oxf) 1974; 3: 69–96.CrossRefGoogle ScholarPubMed
23Huggins, C, Hodges, CV.Studies on prostatic cancer. 1. The effects of castration, of estrogens and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–97.Google Scholar
24Kaisary, AV, Tyrrell, CJ, Peeling, WB, Griffiths, K.Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991; 67: 502–508.CrossRefGoogle ScholarPubMed
25Labrie, F, Dupont, A, Belanger, A et al. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem 1985; 23: 833–41.CrossRefGoogle ScholarPubMed
26Schröder, FH.Hormonal manipulation of prostatic cancer. Br Med J 1991; 303: 1489–90.CrossRefGoogle ScholarPubMed
27Stoner, E.The clinical effects of a 5α-reductase inhibitor, finasteride, on benign prostatic hyperplasia. J Urol 1992; 147: 1298–1302.CrossRefGoogle Scholar
28Tunbridge, WMG, Evered, DC, Hall, R et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977; 7: 481–93.CrossRefGoogle Scholar
29Tunbridge, WMG, Brewis, M, French, JM et al. Natural history of autoimmune thyroiditis. Br Med J 1981; 282: 258–62.CrossRefGoogle ScholarPubMed
30Czarnocka, B, Ruf, J, Ferrand, M et al. Purification of the human thyroid peroxidase and its identification as the microsomal antigen involved in the autoimmune thyroid disease. Febs Lett 1985; 190: 147–52.CrossRefGoogle Scholar
31Takasu, N, Yamada, T, Takas, M et al. Disappearance of thyrotropin-blocking antibodies and spontaneous recovery from hypothyroidism in autoimmune thyroiditis. N Engl J Med 1992; 326: 513–18.CrossRefGoogle ScholarPubMed
32Studer, H.A fresh look at an old thyroid disease: euthyroid and hyperthyroid nodular goitre. J Endocrinol Invest 1982; 5: 57–68.CrossRefGoogle Scholar
33Ollis, CA, Hill, DJ, Munro, DS.A role for insulin-like growth factor-1 in the regulation of thyroid cell growth by thyrotrophin. J Endocrinol 1989; 123: 495–500.CrossRefGoogle ScholarPubMed
34Stewart, JC, Vidor, GI, Buttifield, IH et al. Epidemic thyrotoxicosis in northern Tasmania: studies of clinical features and iodine nutrition. Aust NZ J Med 1971; 3: 203–11.Google Scholar
35Barker, DJP, Phillips, DIW.Current incidence of thyrotoxicosis and past prevalence of goitre in 12 British towns. Lancet 1984; ii: 567–70.CrossRefGoogle Scholar
36Cavalieri, RR, Rapaport, B.Impaired peripheral conversion of thyroxine to triiodothyronine. Am Rev Med 1977; 28: 57–65.CrossRefGoogle ScholarPubMed
37McDevitt, DG.Propranolol in treatment of thyrotoxicosis: a review. Postgrad Med J 1976; 52 (suppl 4): 157–62.Google ScholarPubMed
38Melmed, S, Geola, FL, Reed, AW et al. A comparison of methods for assessing thyroid function in non-thyroidal illness. J Clin Endocrinol Metab 1982; 54: 300–306.CrossRefGoogle Scholar
39Slag, MF, Morley, JE, Elson, MK et al. Hypothyroxinemia in critically ill patients as a predictor of high mortality. JAMA 1981; 245: 43–45.CrossRefGoogle ScholarPubMed
40Spratt, DI, Pont, A, Miller, MB et al. Hyperthyroxinemia in patients with acute psychiatric disorders. Am J Med 1982; 73: 41–48.CrossRefGoogle ScholarPubMed
41Lazarus, JH.Endocrine and metabolic effects of lithium. Adv Drug React Ac Pois Rev 1982; 1: 181–200.Google Scholar
42Gammage, MD, Franklyn, JA.Amiodarone and the thyroid. Q J Med 1987; 62: 83–86.Google ScholarPubMed
43Blum, M, Weinberg, U, Shenkman, L et al. Hyperthyroidism after iodinated contrast of material. N Engl J Med 1974; 291: 24–25.CrossRefGoogle Scholar
44Golding, DN.Hypothyroidism presenting with musculoskeletal symptoms. Ann Rheum Dis 1970; 29: 10–14.CrossRefGoogle ScholarPubMed
45Sachdev, Y, Hall, R.Effusions into body cavities in hypothyroidism. Lancet 1975; i: 564–66.CrossRefGoogle Scholar
46Horton, L, Coburn, RJ, England, JM, Himsworth, RL.The haematology of hypothyroidism. Q J Med 1975; 45: 101–24.Google Scholar
47Sawin, CT, Herman, T, Molitch, ME et al. Aging and the thyroid. Decreased requirement for thyroid hormone in older hypothyroid patients. Am J Med 1983; 75: 206–209.CrossRefGoogle ScholarPubMed
48Belchetz, PE. Emergencies in endocrinology. In: Keynes, WM, Fowler, PBS eds. Tutorials in postgraduate medicine. Clinical endocrinology. London: Heinemann, 1984: 603–35.Google Scholar
49Weinberg, AD, Brennan, MD, Gorman, CA et al. Outcome of anesthesia and surgery in hypothyroid patients. Arch Intern Med 1983; 143: 893–97.CrossRefGoogle ScholarPubMed
50Thomas, FB, Mazzaferri, EL, Skillman, TG.Apathetic thyrotoxicosis: a distinctive clinical and laboratory entity. Ann Intern Med 1970; 72: 679–85.CrossRefGoogle ScholarPubMed
51O'Doherty, M, Croft, D.Radioiodine therapy for thyrotoxicosis. Nuc Med Commun 1992; 13: 391–93.CrossRefGoogle ScholarPubMed
52McDougall, IR. Management of thyroid nodules. In: McDougall, IR.Thyroid disease in clinical practice. London: Chapman & Hall, 1992: 193–206.CrossRefGoogle Scholar
53Morley, JE, Gharib, D. The endocrinology of Alzheimer's disease and late-life depression. In: Morley, JE, Korenman, SG eds. Endocrinology and metabolism in the elderly. Boston: Blackwell, 1992: 111–23.Google Scholar
54Belchetz, PE. Hypopituitarism. In: Belchetz, PE ed. Management of pituitary disease. London: Chapman & Hall, 1984: 103–15.Google Scholar
55Gibbs, DM, Neill, JD.Dopamine levels in hypophysial stalk blood in the rat are sufficient in inhibit prolactin in vivo. Endocrinology 1978; 102: 1895–1900.CrossRefGoogle ScholarPubMed
56Deitala, G. Hyperprolactinaemia: causes, biochemical diagnosis and tests of prolactin secretion. In: Grossman, A ed. Clinical endocrinology. Oxford: Blackwell, 1992: 123–31.Google Scholar
57Romanoff, LP, Morris, CW, Welch, P et al. The metabolism of cortisol – 4–14C in young and elderly men. I: secretion rate of cortisol and daily excretion of tetrahydrocortisol, alleotetrahydrocortisol, tetrahydrocortisone and cortolone (20α and 20β). J Clin Endocrinol Metab 1961; 21: 1413–25.CrossRefGoogle Scholar
58Rao, RH, Spathis, GS.Intramuscular glucagon as a provocative stimulus for the assessment of pituitary function: growth hormone and cortisol responses. Metabolism 1987; 36: 658–63.CrossRefGoogle ScholarPubMed
59Orme, SM, Belchetz, PE.Glucagon stimulation – a final visit? J Endocrinol 1990; 127: Abstract 37.Google Scholar
60Stewart, PM, Corrie, J, Seckl, JR et al. A rational approach for assessing the hypothalamo-pituitaryadrenal axis Lancet 1988; i: 1208.CrossRefGoogle Scholar
61Russell, RWR, Pennybacker, JB.Craniopharyngioma in the elderly. J Neurol Neurosurg Psychiatry 1961; 24: 1–13.CrossRefGoogle ScholarPubMed
62Belchetz, PE.Clinical recognition of idiopathic hypopituitarism in the geriatric patient. Geriatr Med Today 1987; 6: 27–42.Google Scholar
63Belchetz, PE.Postural hypotension and idiopathic hypopituitarism in the elderly. Br Med J 1985; 291: 247–48.CrossRefGoogle Scholar
64Orme, SM, Belchetz, PE.Isolated ACTH deficiency. Clin Endocrinol (Oxf) 1991; 35: 213–17.CrossRefGoogle ScholarPubMed
65Belchetz, PE, Davis, JC, Hipkin, LJ et al. Evaluation of glucagon, clonidine and diazepam as stimulatory tests of growth hormone secretion. J Endocrinol 1986; 108: Abstract 314.Google Scholar
66Shibasaki, T, Shizume, K, Nakahara, M et al. Age related changes in plasma growth hormone response to growth hormone releasing factor in man. J Clin Endocrinol Metab 1984; 58: 212–14.CrossRefGoogle ScholarPubMed
67Saloman, F, Cuneo, RC, Hesp, R, Sönksen, PH.The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989; 321: 1797–1803.CrossRefGoogle Scholar
68Lamberts, SWJ, Valk, NK, Binnerts, A.The use of growth hormone in adults: a changing scene. Clin Endocrinol (Oxf ) 1992; 37: 111–15.CrossRefGoogle ScholarPubMed
69Rudman, D, Feller, AG, Nagraj, HS et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323: 1–6.CrossRefGoogle ScholarPubMed
70Bowers, CY, Newell, DC, Alster, DK. GHRP's – Small GH releasing peptides. Ninth International Congress of Endocrinology, Nice 1992. Symposium 5.2.Google Scholar
71Riggs, BL, Melton, LJ III. Involutional osteoporosis. N Engl J Med 1986; 314: 1676–86.CrossRefGoogle ScholarPubMed
72Marcus, R, Snow-Harter, C. Skeletal aging. In: Morley, JE, Korenman, SG eds. Endocrinology and metabolism in the elderly. Boston: Blackwell, 1992: 153–69.Google Scholar
73Cohn, SH, Abesamis, C, Yasamura, S et al. Comparative skeletal mass and radial bone mineral content in black and white women. Metabolism 1977; 26: 171–78.CrossRefGoogle ScholarPubMed
74Smith, DM, Nance, WE, Kang, KW et al. Genetic factors in determining bone mass. J Clin Invest 1973; 52: 2800–2808.CrossRefGoogle ScholarPubMed
75Dawson-Hughes, B, Dallal, GE, Krall, EA. et al. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1990; 323: 878–83.CrossRefGoogle Scholar
76Nordin, BEC, Polley, KJ.Metabolic consequences of the menopause. A cross sectional, longitudinal, and interventional study on 557 normal postmenopausal women. Calcif Tissue Int 1987; 41 (suppl 1): S1–59.Google Scholar
77Armbrecht, HJ, Boltz, M, Strong, R et al. Expression of calbindin D decreases with age in intestine and kidney. Endocrinology 1989; 125: 2950–56.CrossRefGoogle ScholarPubMed
78Ellis, KJ, Cohn, SH.Correlation between skeletal calcium mass and muscle mass in man. J Appl Physiol 1975; 38: 455–60.CrossRefGoogle ScholarPubMed
79Seeman, E, Melton, LJ III, O'Fallon, WM, Riggs, BL.Risk factors for spinal osteoporosis in men. Am J Med 1983; 75: 977–83.CrossRefGoogle ScholarPubMed
80Eriksen, EF, Colvard, DS, Berg, NJ et al. Evidence of estrogen receptors in normal human osteoblast cells. Science 1988; 241: 84–86.CrossRefGoogle Scholar
81Nicolson, GC, Moseley, JM, Sexton, P, Martin, TJ. Characterization of calcitonin receptors and cychie AMP responses in isolated osteoclasts. In: Cohn, DV, Martin, TJ, Meunier, PJ eds. Calcium regulation and bone metabolism. Amsterdam: Excerpta Medica: 343–48.Google Scholar
82Stevenson, JC, Abeyasekera, G, Hillyard, CJ et al. Calcitonin and the calcium regulating hormones in postmenopausal women: effects of oestrogens. Lancer 1981; i: 693–95.CrossRefGoogle Scholar
83Leichter, I, Margulies, JY, Weinreb, A et al. The relationship between bone density, mineral content and mechanical strength in the femoral neck. Clin Orthop 1982; 163: 272–81.CrossRefGoogle Scholar
85Lindsay, R, Hart, DM, Forest, C et al. Prevention of spinal osteoporosis in oophorectomized women. Lancet 1980; ii: 1151–54.CrossRefGoogle Scholar
86Storm, T, Thamsborg, G, Steiniche, T et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265–71.CrossRefGoogle Scholar
87Watts, NB, Harris, ST, Genant, HK et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73–79.CrossRefGoogle ScholarPubMed
88Orme, SM, Simpson, M, Stewart, SP et al. Possible synergistic effect of high calcium intake and etidronate in osteoporosis. J Endocrinol 1991; 129: Abstract 137.Google Scholar
89Hedlund, LR, Gallagher, JC.Increased incidence of hip fracture in osteoporotic women treated with sodium fluoride. J Bone Miner Res 1989; 4: 223–25.CrossRefGoogle ScholarPubMed
90Heath, H III, Hodgson, SF, Kennedy, MA.Primary hyperparathyroidism: incidence, morbidity, and potential economic impact in a community. N Engl J Med 1980; 302: 189–93.CrossRefGoogle ScholarPubMed
91Palmer, M, Adami, H-O, Bergstrom, R et al. Mortality after surgery for hyperparathyroidism: a followup of 441 patients operated on from 1956 to 1979. Surgery 1987; 102: 1–7.Google ScholarPubMed
92Hamdy, NAT, Gray, RES, McCloskey, E et al. Clodronate in the medical management of hyperparathyroidism. Bone 1987; 8: (suppl 1): 569–77.Google ScholarPubMed
93Peace, K, Page, MD, Barth, JH, Belchetz, PE.Lack of effect of clodronate in mild primary hyperparathyroidism. J Endocrinol 1992; 132: Abstract 125.Google Scholar
94Karstrup, S.Transbøl, I, Holm, HH et al. Ultrasound-guided chemical parathyroidectomy in patients with primary hyperparathyroidism: a prospective study. Br J Radiol 1989; 62: 1037–42.CrossRefGoogle ScholarPubMed
95Graham, K, Williams, BO, Rowe, MJ.Idiopathic hypoparathyroidism: a cause of fits in the elderly. Br Med J 1974; i: 1460–61.Google Scholar
96Eraut, D.Idiopathic hypoparathyroidism presenting as dementia. Br Med J 1974; i: 429–30.CrossRefGoogle Scholar
97Rude, RK, Oldham, SB, Singer, FR.Functional hypoparathyroidism and parathyroid hormone end-organ resistance in human magnesium deficiency. Clin Endocrinol (Oxf) 1976; 5: 209–24.Google ScholarPubMed
98Belchetz, PE. Disorders of the parathyroids. In: Brocklehurst, JC, Tallis, RC, Fillit, H eds. Textbook of geriatric medicine and gerontology, fourth edition. London: Churchill Livingstone, 1992: 717–23.Google Scholar
99Kemp, BE, Moseley, JM, Rodda, CP et al. Parathyroid hormone-related protein of malignancy: active synthetic fragments. Science 1987; 238: 1568–70.CrossRefGoogle ScholarPubMed
100Harvey, JN, Gray, C, Belchetz, PE.Oncogenous osteomalacia in association with benign and malignant tumours. Clin Endocrinol (Oxf) 1992; 37: 379–82.CrossRefGoogle Scholar
101Solomon, A, Weiss, DT, Kattine, AA.Nephrotoxic potential of Bence Jones proteins. N Engl J Med 1991; 324: 1845–51.CrossRefGoogle ScholarPubMed
102Hordon, LD, Peacock, M.Vitamin D metabolism in women with femoral neck fracture. Bone Miner 1987; 2: 413–26.Google ScholarPubMed
103Belchetz, PE. Pituitary adrenal disorders in old age. In: Brocklehurst, JC, Tallis, RC, Fillit, H eds. Textbook of geriatric medicine and gerontology, fourth edition. London: Churchill Livingstone, 1992: 694–700.Google Scholar
104Geellhoed, GW, Druy, EM.Management of the adrenal ‘incidentaloma’. Surgery 1982; 92: 866–74.Google Scholar
105Virkkala, A, Valimaki, M, Pelkonen, R et al. Endocrine abnormalities in patients with adrenal tumors incidentally discovered on computed tomography. Acta Endocrinol (Copenh) 1989; 121: 67–72.Google ScholarPubMed